Arranta Bio Announces the Acquisition of Captozyme™, Creating a Center of Excellence for Microbiome Development and Clinical Supply

Arranta Bio, a contract development and manufacturing organization (CDMO), announced the acquisition of UF Innovate alumni startup Captozyme^™, a leader in health care for and through the gut using novel enzymes and live biotherapeutics. With the acquisition, Arranta Bio will establish its Center of Excellence for process and analytical development and early clinical supply for microbiome clients with the transfer of the Captozyme team and facilities in Gainesville to Arranta.

Formed in 2009, Captozyme has been the leader in providing development services to microbiome pioneers with a team that has developed processes for over 125 different species and 80 different genera over the past decade. In 2018, Captozyme established GMP clinical capacity and has successfully scaled processes to 400L scale fermentation through to lyophilization and encapsulation. The team has built significant know-how of handling, scaling, processing, and encapsulation of strict anaerobes.

Learn more about Arranta Bio Announces the Acquisition of Captozyme™, Creating a Center of Excellence for Microbiome Development and Clinical Supply.